SNSE Sensei Biotherapeutics, Inc.

Nasdaq senseibio.com


$ 11.97 $ 0.53 (4.71 %)    

Monday, 13-Oct-2025 15:55:16 EDT
QQQ $ 595.46 $ 0.00 (0 %)
DIA $ 458.32 $ 0.00 (0 %)
SPY $ 657.57 $ 0.00 (0 %)
TLT $ 90.85 $ 0.00 (0 %)
GLD $ 380.85 $ 0.00 (0 %)
$ 11.79
$ 11.26
$ 11.00 x 4
$ 12.50 x 3
-- - --
$ 5.00 - $ 17.40
3,656
na
14.87M
$ 5.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-15-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-sensei-biotherapeutics-raises-price-target-to-30

HC Wainwright & Co. analyst Joseph Pantginis maintains Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and raises the pr...

 sensei-biotherapeutics-to-implement-1-for-20-reverse-stock-split-of-issued-and-outstanding-shares-effective-june-16-2025

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of ...

 hc-wainwright--co-assumes-sensei-biotherapeutics-at-buy-announces-price-target-of-5

HC Wainwright & Co. analyst Matthew Kelsey assumes Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and announces ...

 sensei-biotherapeutics-q1-eps-027-misses-022-estimate

Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate...

 sensei-biotherapeutics-reports-favorable-initial-clinical-activity-data-for-solnerstotug-in-resistant-tumors

Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION